Daniel Pella
Disorders of lipid metabolism characterized by increased level of atherogenic particles or by decrease in protective fractions – dyslipidemias – are very important risk factor of atherosclerosis in all their forms and locations. There is evidence from large number of clinical trials that successfull treatment of dylipidemias is leading not only to decrease of cardiovascular and cerebrovascular endpoints, reduction of cardiovascular mortality, but also to significant reduction of total mortality. Despite these facts there is still some gap in common clinical practice in contrast with results of these trials which should be in association with unsatisfactory evaluation of patients risk profile, eventually inadequate choice of lipid lowering drug and its dosage.
Key words : dyslipidemia, lipid lowering drugs, statins, fibrates